Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

TDP-43 regulates LC3ylation in neural tissue through ATG4B cryptic splicing inhibition.

Torres P. et al, (2024), Acta Neuropathol, 148

Multiple surgical resections for progressive IDH wildtype glioblastoma-is it beneficial?

Honeyman SI. et al, (2024), Acta Neurochir (Wien), 166

A transcriptomics-based drug repositioning approach to identify drugs with similar activities for the treatment of muscle pathologies in spinal muscular atrophy (SMA) models.

Hoolachan JM. et al, (2024), Hum Mol Genet, 33, 400 - 425

Scalable purification of extracellular vesicles with high yield and purity using multimodal flowthrough chromatography.

Bonner SE. et al, (2024), J Extracell Biol, 3

Why is early-onset atrial fibrillation uncommon in patients with Duchenne Muscular Dystrophy? Insights from the mdx mouse.

Nguyen M-N. et al, (2024), Cardiovasc Res

Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression.

González-Martínez I. et al, (2023), Mol Ther Nucleic Acids, 34

Therapeutic approaches for Duchenne muscular dystrophy.

Roberts TC. et al, (2023), Nat Rev Drug Discov, 22, 917 - 934

An Induced Pluripotent Stem Cell-Derived Human Blood-Brain Barrier (BBB) Model to Test the Crossing by Adeno-Associated Virus (AAV) Vectors and Antisense Oligonucleotides.

Selvakumaran J. et al, (2023), Biomedicines, 11

PRMT inhibitor promotes SMN2 exon 7 inclusion and synergizes with nusinersen to rescue SMA mice.

Kordala AJ. et al, (2023), EMBO Mol Med

Modulation of Pro-Inflammatory IL-6 Trans-Signaling Axis by Splice Switching Oligonucleotides as a Therapeutic Modality in Inflammation.

Gupta D. et al, (2023), Cells, 12

A Purposefully Designed pH/GSH-Responsive MnFe-Based Metal-Organic Frameworks as Cascade Nanoreactor for Enhanced Chemo-Chemodynamic-Starvation Synergistic Therapy.

Chen WJ. et al, (2023), Small

Investigating Eukaryotic Elongation Factor 2 Kinase/Eukaryotic Translation Elongation Factor 2 Pathway Regulation and Its Role in Protein Synthesis Impairment during Disuse-Induced Skeletal Muscle Atrophy.

Vilchinskaya N. et al, (2023), Am J Pathol, 193, 813 - 828

Tumor-targeted glycogen nanoparticles loaded with hemin and glucose oxidase to promote tumor synergistic therapy.

Qiu L. et al, (2023), Int J Biol Macromol, 239

Engineered bacteria combined with doxorubicin nanoparticles suppress angiogenesis and metastasis in murine melanoma models.

Yang M. et al, (2023), Acta Biomater, 158, 734 - 746

Comparison of different methods for isolating CD8+ T lymphocyte-derived extracellular vesicles and supramolecular attack particles

Jainarayanan A. et al, (2023), Journal of Extracelluar Biology

Oral delivery of layer-by-layer coated exosomes for colitis therapy.

Deng C. et al, (2023), J Control Release, 354, 635 - 650

Application of Antisense Conjugates for the Treatment of Myotonic Dystrophy Type 1.

Stoodley J. et al, (2023), Int J Mol Sci, 24

Biodistribution of therapeutic extracellular vesicles

Gupta D. et al, (2023), Extracellular Vesicles and Circulating Nucleic Acids, 4, 170 - 190

Peptide-Conjugated PMOs for the Treatment of Myotonic Dystrophy.

Stoodley J. et al, (2023), Methods Mol Biol, 2587, 209 - 237

Non-uniform dystrophin re-expression after CRISPR-mediated exon excision in the dystrophin/utrophin double-knockout mouse model of DMD.

Hanson B. et al, (2022), Mol Ther Nucleic Acids, 30, 379 - 397

Load More

1
2
3
4
5
6
7
...
»

Include forthcoming?